Invokana Drug Lawsuit Source

Invokana Recall: Invokana Side Effects Recall Information

Important Invokana recall information:

Invokana Recall

The U.S. Food and Drug Administration has not yet issued a recall for Invokana despite the drug being linked to serious, life-threatening complications.

As the FDA continues to investigate potential complications caused by Invokana, claims are being investigated against the drug manufacturer for failing to produce a safe and reliable medication.

What are the Criteria for Filing an Invokana Lawsuit?

Approved in March 2013, Invokana (canagliflozin) is an SGLT2 Inhibitor used to treat adults with Type 2 diabetes, manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

SGLT2 inhibitors work by preventing high blood sugar by helping the patient’s kidneys remove excess sugar through their urine.

In May 2015, the U.S. Food and Drug Administration (FDA) issued a warning the drug has been linked to cases of ketoacidosis, a serious condition where there is too much acid in the blood.

Complications of diabetic ketoacidosis include difficulty breathing, nausea/vomiting, abdominal pain, confusion and unusual fatigue or sleepiness. The condition can lead to diabetic coma and/or death.

Can I File an Invokana Lawsuit?

If you or a loved one have taken Invokana and developed complications which you believe have been caused by the drug, you may be entitled to file a lawsuit to recover compensation. Settlements in Invokana lawsuits are expected to be substantial, as they take into account your personal pain and suffering, disability, lost income, medical expenses, and psychological harm.

The national Invokana lawsuit alleges that the manufacturers and marketers of SGLT2 Inhibitors failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues, and ketoacidosis.

The lawsuit states that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes and would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.

If you suffered severe complications from taking an SGLT2 Inhibitor, you may be entitled to compensation. Below is the criteria required to file an SGLT2 Inhibitor lawsuit:

  • Patient has taken Invokana, Invokamet, Farxiga, Glyxambi, Jardiance, or Xigduo XR and suffered one or more of the following:
    • Kidney failure
    • Diabetic Ketoacidosis
    • Heart attack
    • Stroke
    • Death
    • Dehydration requiring hospitalization
    • Bone fracture
    • Amputation

Our dangerous drug attorneys can help if you believe you were harmed by Invokana. Claims continue to be investigated against Janssen Pharmaceutica, the producers of the drug, by both patients and their families seeking compensation for suffering they have endured. You may be entitled to a settlement.

Is There a TV Commercial about Invokana Lawsuits?

Our No-Fee Promise on Invokana Lawsuits

You can afford to have our great team of Invokana lawyers on your side. When you choose us, it costs you nothing to get started. We promise you in writing:

  • No money to get started
  • We pay all case costs and expenses
  • No legal fees whatsoever unless you receive a settlement
  • Phone calls are always free

Start Your Invokana Lawsuit

To get started on your Invokana claim, you can:

  1. Submit the Free Case Review Box on this page, or
  2. Call (866) 280-3417 any time of day to tell us about your case.

We will listen to your story and answer your questions. If you have a claim, we will start immediately.

WARNING: There are strict time deadlines for filing Invokana lawsuit claims.

Invokana Lawyer Review

Drug Lawsuit Source Client Review
Review Date
Reviewed
Prescription Drug Lawyer
Client Rating
51star1star1star1star1star

View Sources

  1. Invokana (canagliflozin) tablets – FDA
  2. Drug Safety Communication – FDA
  3. Drug Safety Communication – FDA

References